( MENAFN - PR Newswire) BETHESDA, Md., Oct. 23, 2024 /PRNewswire/ -- The National Institutes of health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
The trial, funded by NIH's National Cancer Institute (NCI), aims to accelerate the discovery of more tailored treatments for these aggressive cancers of the blood and bone marrow. "NCI is uniquely positioned to conduct this type of study, which is one of a series of NCI precision medicine trials that are helping pave the way for more personalized treatment of cancer," said W. Kimryn Rathmell, M.
D., Ph.D.
, director of NCI. "By making these trials available to patients in communities around the country, we bring cutting edge science to people where they live and ensure that what we learn from our study participants can benefit patients like them in the future." "AML and MDS are a heterogeneous group of cancers that can progress very quickly.
Treatment advances depend in part on the ability to rapidly identify which subtype of cancer each patient has so that treatments can be tested for their specific cancer," said Richard F. Little, M.D.
, of NCI's Division of Cancer Treatment and Diagnosis. Dr. Little is the NCI coordinator for the trial, known as the Myeloid Malignancies Molecular Analysis for Therapy Choice (myeloMATCH) .
"The goal of m.
